HORMONE REFRACTORY PROSTATE CANCER: NEW STUDIES IN AUSTRIA
• Three clinical trials started at the Medical University of Vienna
• Commissioned by multinational pharmaceutical firms
(firmenpresse) -
Vienna, 29 March 2010 – The Medical University of Vienna has been commissioned by
international pharmaceutical firms to conduct three clinical trials of the treatment of
recurrent prostate tumors (hormone refractory prostate carcinomas). The new approaches
comprise immunotherapy, hormone therapy and an augmented form of the current
standard treatment with docetaxel.
Team leader Prof. Dr. Michael Krainer and his colleagues will concentrate primarily on
tumors diagnosed late or those which recur after surgical interventions, and which do not
(or no longer) respond to common treatments such as androgen deprivation.
IMMUNOTHERAPY
The team will investigate the use of the monoclonal antibody ipilimumab as part of the
immunotherapeutic treatment. This antibody can cause the body's own immune system to
react against cancer cells. Prof. Krainer said that "the use of ipilimumab rather than
docetaxel has led to rather surprising successes during the past year in a small-scale trial.
In three patients, a tumor that had been hard to treat became so small that it could be
surgically removed. Since a small-scale trial of this nature only allows limited claims to be
made about the drug, ipilimumab is now being investigated further in a larger study."
HORMONE THERAPY
A hormone treatment based on the drug MDV3100 is also being trialed by the team at the
Medical University of Vienna. This is used as a second-line treatment after the initial
treatment with docetaxel. MDV3100 is a substance that blocks the androgen receptor and
thus offers a new approach to the prevention of hormone dependent tumor growth.
AUGMENTED STANDARD TREATMENT
In the past, Prof. Krainer and his team were able to show the efficacy of docetaxel versus
other common chemotherapeutic drugs. The third trial at the Medical University of Vienna
will test the combination of docetaxel with the tyrosine kinase inhibitor sunitinib. As part of
the trial, the researchers will examine biomarkers in the patients' blood that will yield
information about the progress of the treatment.
TOP QUALITY RESEARCH IN AUSTRIA
"We are delighted that multinational pharmaceutical companies find in Austria the optimal
environment and competent partners for clinical trials and basic research", said Dr. René
Siegl, Managing Director of the Austrian investment promotion company ABA-Invest in
Austria. "This shows that the conditions at the location Austria are ideal". More than 15
percent of Austrian R&D expenditure comes from foreign commissions. With 2.73 percent
of the GNP in 2009 being spent on research, Austria has closed the gap with other
European countries at the forefront of innovation. The aim is a research quota of 4 percent
by 2020. In future Austria will create even greater incentives for businesses to attract
innovation centers and will further develop collaborative endeavors between the scientific
and business worlds.
Note to editors:
ABA – Invest in Austria is an investment promotion company owned by the Austrian
Ministry of the Economy. It provides free advice to interested businesses in the following
areas: choosing a location, navigating employment and tax law, finding partners for joint
ventures, and dealing with official bodies. ABA – Invest in Austria's staff support
businesses from its headquarters in Vienna and its branch offices in New York and Tokyo.
For further information please contact:
Hanni Grassauer
ABA - Invest in Austria
Opernring 3
1010 Wien, Austria
T +43 / 1 / 588 58 57
F +43 / 1 / 586 86 59
E h.grassauer(at)aba.gv.at
W http://www.investinaustria.at
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 29.03.2010 - 09:33 Uhr
Sprache: Deutsch
News-ID 1012121
Anzahl Zeichen: 0
contact information:
Contact person: Marta Korinkova
Town:
Vienna
Phone: + 43 1 505 70 44
Kategorie:
Research & Development
Anmerkungen:
Diese Pressemitteilung wurde bisher 336 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"HORMONE REFRACTORY PROSTATE CANCER: NEW STUDIES IN AUSTRIA
"
steht unter der journalistisch-redaktionellen Verantwortung von
PR&D - Public Relations for Research & Education (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
